Immutep Announced Earlier It Will Present Overall Survival Data In1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation At ESMO Congress 2023
Portfolio Pulse from Charles Gross
Immutep Limited announced that its TACTI-002 Phase II trial data for the treatment of 1st line non-small cell lung cancer has been accepted for presentation at the 2023 European Society for Medical Oncology Congress. The data pertains to the combination of eftilagimod alpha and KEYTRUDA, Merck & Co.'s anti-PD-1 therapy.
July 31, 2023 | 8:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep's announcement of its trial data presentation at a major medical congress could potentially boost investor confidence in the company's ongoing research and development efforts.
The acceptance of Immutep's trial data for presentation at a major medical congress signifies recognition from the medical community. This could potentially boost investor confidence in the company's ongoing research and development efforts, leading to a positive impact on its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Merck & Co.'s involvement in Immutep's trial through its anti-PD-1 therapy, KEYTRUDA, could potentially enhance its reputation in the field of cancer treatment.
Merck & Co.'s KEYTRUDA is part of the trial data to be presented by Immutep. This association could potentially enhance Merck's reputation in the field of cancer treatment, leading to a positive impact on its stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50